Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Allergan Reports Strong First Quarter 2016 Continuing Operations Performance with 48% Increase in Net Revenue to $3.8 Billion and 15% Growth in Non-GAAP Diluted EPS to $3.04

Allergan plc (AGN): Incrementally Cautious - Piper Jaffray

May 11, 2016 7:46 AM EDT

Piper Jaffray analyst, David Amsellem, is cautious on Allergen (NYSE: AGN) despite bright spots in the quarter. The company needs incremental products to growth the top line leaving the path to growth murky.

AGN reported non-GAAP diluted EPS of $3.04 on revenues of $3.8B,... More

Allergan (AGN) Tops Q1 EPS by 1c

May 10, 2016 7:31 AM EDT

Allergan (NYSE: AGN) reported Q1 EPS of $3.04, $0.01 better than the analyst estimate of $3.03. Revenue for the quarter came in at $3.8 billion versus the consensus estimate of $3.96 billion.

Allergan's full year 2016 continuing operations standalone estimates are based on management's current belief about prescription trends,... More